Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
07:30am, Thursday, 20'th Feb 2025
GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202
ALT5 Sigma Adds the Official $TRUMP Coin to Its Trading and Payment Platforms
08:30am, Tuesday, 18'th Feb 2025
ALT5 Pay Merchants can now accept $TRUMP for payments, with seamless USD or stablecoin conversion. LAS VEGAS, NV / ACCESS Newswire / February 18, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
05:26am, Tuesday, 18'th Feb 2025
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase
ALT5 Nominated for SiGMA Best Online Payment Services 2025, Exhibiting at SiGMA Eurasia in Dubai, February 23-25
03:00pm, Thursday, 13'th Feb 2025
LAS VEGAS, NEVADA / ACCESS Newswire / February 13, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech company specializing in next-generation blockchain-powered technologies for tokenizati
ALT5 Sigma Partners With Odoo to Offer Crypto Payments Capabilities Through Odoo Marketplace
07:30am, Monday, 03'rd Feb 2025
-Odoo is the most installed business software in the world, used by over 13,000,000 users worldwide ranging from startup companies (1 user) to large enterprises (300,000+ users)- LAS VEGAS, NV / ACCES
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
07:30am, Wednesday, 29'th Jan 2025
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing
07:00am, Wednesday, 15'th Jan 2025
LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer,
ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025
11:30am, Thursday, 09'th Jan 2025
LAS VEGAS, NEVADA / ACCESSWIRE / January 9, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settl
Altimmune Could Find A Partner For Its Phase 3 Exercise
11:42am, Monday, 30'th Dec 2024
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
06:35pm, Thursday, 19'th Dec 2024
Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized s
Altimmune Added to Nasdaq Biotechnology Index
07:30am, Thursday, 19'th Dec 2024
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index
ALT5 Sigma Announces Results of 2024 AGM and Corporate Update
04:00pm, Wednesday, 18'th Dec 2024
All resolutions were approved LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a leading fintech firm offering next-generation blockchai
Altimmune 2025: Redefining Obesity And MASH Treatment
03:14am, Monday, 16'th Dec 2024
Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety
Altimmune CEO on what's next for its experimental obesity drug
06:04pm, Tuesday, 03'rd Dec 2024
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.
Altimmune Stock Up More Than 25% in a Month: Here's Why
10:31am, Monday, 02'nd Dec 2024
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
